Progenity to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Progenity, a biotechnology company listed on Nasdaq under the symbol PROG, announced that CEO Harry Stylli will participate in two virtual investor conferences. The first presentation will be at Baird's 2020 Global Healthcare Conference on September 9, 2020, at 12:15 p.m. ET, followed by an analyst-led group meeting at the Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 12:40 p.m. ET. Live audio webcasts for both events will be available on Progenity's website, along with archived replays.

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, is scheduled to participate in two upcoming virtual investor conferences:

• A presentation at Baird’s 2020 Global Healthcare Conference at 12:15 p.m. ET / 9:15 a.m. PT on September 9, 2020; and

• An analyst-led group meeting at the 2020 Wells Fargo Virtual Healthcare Conference at 12:40 p.m. ET / 9:40 a.m. PT on September 10, 2020.

A live audio webcast of the Baird presentation and the Wells Fargo group meeting will be available in the Investors section of Progenity’s website at https://www.progenity.com, with an archived replay available following the events.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
kblomlowery@cglife.com
(858) 457-2436

FAQ

When will Progenity's CEO participate in investor conferences?

Harry Stylli, CEO of Progenity, will present at the Baird's 2020 Global Healthcare Conference on September 9, 2020, and at the Wells Fargo Virtual Healthcare Conference on September 10, 2020.

What is the schedule for Progenity's upcoming conferences?

The Baird presentation is scheduled for September 9, 2020, at 12:15 p.m. ET, and the Wells Fargo meeting is on September 10, 2020, at 12:40 p.m. ET.

Will Progenity provide access to the conference presentations?

Yes, Progenity will have live audio webcasts of the presentations available on their website, with archived replays after the events.

Where can I find more information about Progenity?

For additional information about Progenity and their products, visit their website at www.progenity.com.